Kadmon Holdings, Inc.: management transactions · United States · SEC (Form 4)

About Kadmon Holdings, Inc.

Kadmon Holdings, Inc. was a U.S.-based biopharmaceutical company historically listed on the NASDAQ under the ticker KDMN before being taken private through Sanofi’s acquisition, which was completed in November 2021. For French-speaking investors in France, Belgium, and Switzerland, Kadmon is a classic specialty-biotech case: a research-driven company built around a focused scientific platform, high regulatory optionality, and a concentrated asset base rather than a broad commercial portfolio. The company was founded in 2009 in New York, United States, and its historical headquarters and core operations were also in New York, reflecting its location within one of the most important U.S. biotech financing and talent hubs. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1557142/000155714221000022/kdmn-20201231x10k.htm?utm_source=openai)) Kadmon’s business model centered on discovering, developing, and commercializing therapies for serious unmet medical needs, with a strong emphasis on immune-mediated and fibrotic diseases. Its lead asset was REZUROCK (belumosudil), an orally administered selective ROCK2 inhibitor. In July 2021, the FDA granted full approval to REZUROCK for adult and pediatric patients aged 12 and older with chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy. That regulatory milestone was transformational: it validated the underlying science, established the company’s first major commercial franchise, and materially improved the strategic attractiveness of the business. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1557142/000155714221000062/kdmn-20210719x8k.htm?utm_source=openai)) From a competitive standpoint, Kadmon operated in a highly specialized segment of the U.S. biopharma market. Companies in this category typically compete on clinical differentiation, speed to approval, reimbursement access, and physician adoption rather than scale. Kadmon’s profile was therefore more akin to an innovation-led niche developer than a diversified pharmaceutical group. Beyond REZUROCK, the company also referenced development programs in immuno-oncology and other immune/fibrotic indications, which suggested a pipeline strategy designed to extend the value of its scientific platform over time. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1557142/000155714221000022/kdmn-20201231x10k.htm?utm_source=openai)) A major recent corporate event was the Sanofi transaction. Sanofi announced the acquisition of Kadmon in September 2021 and completed it on November 9, 2021, stating that REZUROCK would strengthen its transplant business and broader general medicines portfolio. For investors, this is crucial context: Kadmon is no longer a standalone publicly traded issuer on the NASDAQ/NYSE in the United States, but it remains relevant as an M&A precedent and as an issuer that generated meaningful insider-transaction and SEC filing activity before the deal closed. Its short public-market history illustrates how a single FDA-approved asset can rapidly re-rate a biotech and ultimately trigger a strategic exit. ([globenewswire.com](https://www.globenewswire.com/news-release/2021/11/09/2330525/0/en/Sanofi-completes-acquisition-of-Kadmon.html?utm_source=openai))